Jun 28,2023

ARD-2128是一種PROTAC AR降解劑，具有出色的血漿和微粒體穩定性，本研究中體外穩定性和PK研究通過尊龍凱時進行

ARD-2128 has excellent plasma and microsomal stability in all the five species (Human, Mouse, Rat, Dog, and Monkey). The in vitro stability and pharmacokinetic (PK) studies were performed by Medicilon.

Jun 28,2023

設計合成一系列DHODH抑制劑作為潛在的類風濕性關節炎治療藥物，本研究中PK實驗通過尊龍凱時進行

Human dihydroorotate dehydrogenase (DHODH) is a viable target for the development of therapeutics to treat cancer and immunological diseases. Herein, researchers designed and synthesized a series of acrylamide-based novel DHODH inhibitors as potential rheumatoid arthritis (RA) treatment agents.

Jun 28,2023

開發并驗證新的LC-MS/MS方法，用于定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。本研究中OHD(純度>99%)通過尊龍凱時合成

OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.

Jun 28,2023

放射療法用作肺癌的主要治療方法，本研究中建立抗電離輻射肺癌細胞系的放射治療通過尊龍凱時進行

Radiation therapy is used as the primary treatment for lung cancer. In this study, radiation therapy for establish ionizing radiation-resistant lung cancer cell lines (A549-IR/H1299-IR) was supported by Medicilon.

Jun 28,2023

CAR-T療法主要針對白血病與惡性淋巴瘤，本研究中構建沉默PD-1的shRNA載體質粒，測序后質粒的鑒定通過尊龍凱時進行

Chimeric antigen receptor T cells (CAR-T) immunotherapy has shown promising clinical results in the treatment of leukemia and lymphoma, but the effectiveness is limited for solid tumors. The shRNA vector plasmid that silences PD-1 and preparation of CAR is constructed. The plasmids sequenced were fully identified by Medicilon.

Jun 28,2023

索拉非尼的無定形固體分散體用于開發改良型口服生物利用度高的速釋片劑，本研究中PK實驗通過尊龍凱時進行

The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar?. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar? tablets was performed by Medicilon.

Jun 28,2023

TAK-931是一種高特異性CDC7抑制劑，具有抗腫瘤功效，本研究中體內藥效實驗通過尊龍凱時進行

In vivo efficacy studies in J558 allograft models in combination with anti-mPD-1, anti-mPD-L1, and anti-mCTLA-4 antibodies were performed at Medicilon.

Jun 28,2023

GS-5801是一種高效KDM5抑制劑，具有抗HBV活性，本研究中GS-5801通過尊龍凱時合成

GS-5801, a potent inhibitor of KDM5, has antiviral activity against HBV in a primary human hepatocytes infection model, with the cellular permeability, oral bioavailability. GS-5801 was synthesized by Medicilon.

Jun 28,2023

QF-036是一種高效的HIV-1抑制劑，具有良好的和藥代動力學特性，PK研究通過尊龍凱時進行

The favourable viral inhibitory activity and pharmacokinetic properties provide critical support for QF-036 as a promising anti-HIV therapeutic candidate. The pharmacokinetic studies were performed by Medicilon.

Jun 28,2023

設計合成一種新型選擇性的口服有效蘇氨酸酪氨酸激酶 (TTK) 抑制劑，PK研究均通過尊龍凱時進行

TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.